Overview

* Cytokinetics ( CYTK ) Q3 net loss widens to $306.2 mln, driven by debt conversion expense

* Company reports Q3 revenue of $1.9 mln, up from $0.5 mln last year

* Cytokinetics ( CYTK ) prepares for potential U.S. launch of aficamten pending FDA approval

Outlook

* Company expects EMA decision on aficamten MAA in 1H 2026

* Company updates 2025 GAAP operating expense guidance to $680 mln-$700 mln

* Cytokinetics ( CYTK ) prepares for aficamten U.S. commercial launch post-PDUFA date

Result Drivers

* FDA INTERACTIONS - Co progressing towards Dec 2025 PDUFA date for aficamten, with strategic commercial preparations underway

* R&D EXPENSES: or the third quarter of 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$306.18

Income mln

Q3 Basic -$2.55

EPS

Q3 $168.69

Operatin mln

g

Expenses

Q3 -$166.76

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Cytokinetics Inc ( CYTK ) is $79.00, about 24.5% above its November 4 closing price of $59.62

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)